ISDA

Deposition Date 2025-01-09

Release Date 2025-05-28

Last Version Date 2025-05-28

Entry Detail

PDB ID:

9MSD

Keywords:

VIRAL PROTEIN/IMMUNE SYSTEM

Title:

G002-293-0536 Fab in complex with 001428_T278M_L14 SOSIP and RM20A3 Fab

Biological Source:

Source Organism:

Human immunodeficiency virus 1 (Taxon ID: 11676)
Homo sapiens (Taxon ID: 9606)
Macaca mulatta (Taxon ID: 9544)

Host Organism:

Homo sapiens

Method Details:

Experimental Method:

ELECTRON MICROSCOPY

Resolution:

3.20 Å

Aggregation State:

PARTICLE

Reconstruction Method:

SINGLE PARTICLE

Download Validation Report

Macromolecular Entities

Protein Blast

Polymer Type:polypeptide(L)
Molecule:001428_T278M_L14 SOSIP gp140
Chain IDs:A, F (auth: G), K (auth: B)
Chain Length:650
Number of Molecules:3
Biological Source:Human immunodeficiency virus 1

UniProt ID:A0A0B5KZH3

Polymer Type:polypeptide(L)
Molecule:RM20A3 Rab heavy chain
Chain IDs:E (auth: C), J (auth: E), O (auth: J)
Chain Length:228
Number of Molecules:3
Biological Source:Macaca mulatta

Polymer Type:polypeptide(L)
Molecule:RM20A3 Fab light chain
Chain IDs:D, I (auth: F), N (auth: K)
Chain Length:215
Number of Molecules:3
Biological Source:Macaca mulatta

Polymer Type:polypeptide(L)
Molecule:G002-293-0536 Fab heavy chain
Chain IDs:B (auth: H), G (auth: I), L (auth: N)
Chain Length:224
Number of Molecules:3
Biological Source:Homo sapiens

Polymer Type:polypeptide(L)
Molecule:G002-293-0536 Fab light chain
Chain IDs:C (auth: L), H (auth: M), M (auth: O)
Chain Length:210
Number of Molecules:3
Biological Source:Homo sapiens

Ligand Molecules

NAG

Primary Citation

Vaccination with mRNA-encoded nanoparticles drives early maturation of HIV bnAb precursors in humans.

Willis, J.R, Prabhakaran, M, Muthui, M, Naidoo, A, Sincomb, T, Wu, W, Cottrell, C.A, Landais, E, deCamp, A.C, Keshavarzi, N.R, Kalyuzhniy, O, Lee, J.H, Murungi, L.M, Ogonda, W.A, Yates, N.L, Corcoran, M.M, Phulera, S, Musando, J, Tsai, A, Lemire, G, Sein, Y, Muteti, M, Alamuri, P, Bohl, J.A, Holman, D, Himansu, S, Leav, B, Reuter, C, Lin, L.A, Ding, B, He, C, Straus, W.L, MacPhee, K.J, Regadas, I, Nyabundi, D.V, Chirchir, R, Anzala, A, Kimotho, J.N, Kibet, C, Greene, K, Gao, H, Beatman, E, Benson, K, Laddy, D, Brown, D.M, Bronson, R, Baptiste, J, Gajjala, S, Rikhtegaran-Tehrani, Z, Benner, A, Ramaswami, M, Lu, D, Alavi, N, Amirzehni, S, Kubitz, M, Tingle, R, Georgeson, E, Phelps, N, Adachi, Y, Liguori, A, Flynn, C, McKenney, K, Zhou, X, Owuor, D.C, Owuor, S, Kim, S.Y, Duff, M, Kim, J.Y, Gibson, G, Baboo, S, Diedrich, J, Schiffner, T, Shields, M, Matsoso, M, Santos, J, Syvertsen, K, Kennedy, A, Schroeter, M, Vekemans, J, Yates, J, Paulson, J.C, Hyrien, O, McDermott, A.B, Maenetje, P, Nyombayire, J, Karita, E, Ingabire, R, Edward, V, Muturi-Kioi, V, Maenza, J, Shapiro, A.E, McElrath, M.J, Edupuganti, S, Taylor, B.S, Diemert, D, Ozorowski, G, Koup, R.A, Montefiori, D, Ward, A.B, Hedestam, G.K, Tomaras, G, Hunt, D.J, Muema, D, Sok, D, Laufer, D.S, Andrews, S.F, Nduati, E.W, Schief, W.R.Show

Science ? eadr8382 eadr8382 (2025)

PMID: 40373112 DOI: 10.1126/science.adr8382

Abstact

A leading HIV vaccine strategy requires a priming immunogen to induce broadly neutralizing antibody (bnAb) precursors, followed by a series of heterologous boosters to elicit somatic hypermutation (SHM) and produce bnAbs. In two randomized, open-label phase 1 human clinical trials, IAVI-G002 in the United States and IAVI-G003 in Rwanda and South Africa, we evaluated the safety and immunogenicity of mRNA-encoded nanoparticles as priming immunogens (both trials) and first-boosting immunogens (IAVI-G002). The vaccines were generally safe and well tolerated, except 18% of IAVI-G002 participants experienced skin reactions. Priming induced bnAb precursors with substantial frequencies and SHM, and heterologous boosting elicited increased SHM, affinity, and neutralization activity toward bnAb development. The results establish clinical proof of concept that heterologous boosting can advance bnAb-precursor maturation and demonstrate bnAb priming in Africa where the HIV burden is highest.

Legend

Protein

Chemical

Disease

Primary Citation of related structures